[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100563356":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":28,"centralContacts":33,"locations":41,"responsibleParty":82,"collaborators":84,"id":87,"slug":88,"hasResults":89,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":89,"sex":95,"minAge":96,"maxAge":24,"enrollmentInfo":97,"targetDuration":24,"studyType":100,"phases":101,"briefSummary":103,"conditions":104,"keywords":107,"overallStatus":44,"whyStopped":24,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":119},{"fullName":5,"class":6},"Universität Münster","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Angiotensin II","EXPERIMENTAL","Intravenous infusion through a central line according to the patient's situation. Target medium arterial pressure (MAP): \\>65mmHg",[13],"Drug: Angiotensin II",{"label":15,"type":16,"description":11,"interventionNames":17},"Control","ACTIVE_COMPARATOR",[18],"Drug: Noradrenalin",[20,25],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Intravenous infusion through a central line according to the patient's situation. Once an infusion is established, the dose will be titrated as frequently as every 5 minutes, as needed, depending on the patient's condition and target MAP.",[9],null,{"type":21,"name":26,"description":22,"armGroupLabels":27,"otherNames":24},"Noradrenalin",[15],[29],{"name":30,"affiliation":31,"role":32},"Alexander Zarbock, MD","University Hospital Muenster, Dept. of Anesthesiology, Intensive Care Medicine and Pain Therapy","PRINCIPAL_INVESTIGATOR",[34,38],{"name":30,"role":35,"phone":36,"phoneExt":24,"email":37},"CONTACT","+49-251-8347252","PAN-AKI@ukmuenster.de",{"name":39,"role":35,"phone":40,"phoneExt":24,"email":37},"Melanie Meersch-Dini, MD","+49-251-8347255",[42,55,64,73],{"facility":43,"status":44,"city":45,"state":24,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":24},"Deutsches Herzzentrum der Charité","RECRUITING","Berlin","13353","Germany","DE",{"type":50,"coordinates":51},"Point",[52,53],13.41053,52.52437,{"lat":53,"lon":52},{"facility":56,"status":44,"city":57,"state":24,"zip":58,"country":47,"countryCode":48,"cosmosGeoPoint":59,"geoPoint":63,"contacts":24},"University Hospital Bonn","Bonn","53127",{"type":50,"coordinates":60},[61,62],7.09549,50.73438,{"lat":62,"lon":61},{"facility":65,"status":44,"city":66,"state":24,"zip":67,"country":47,"countryCode":48,"cosmosGeoPoint":68,"geoPoint":72,"contacts":24},"University Medical Center Mainz","Mainz","55131",{"type":50,"coordinates":69},[70,71],8.28008,49.98185,{"lat":71,"lon":70},{"facility":74,"status":44,"city":75,"state":24,"zip":76,"country":47,"countryCode":48,"cosmosGeoPoint":77,"geoPoint":81,"contacts":24},"University Hospital Münster","Münster","49149",{"type":50,"coordinates":78},[79,80],7.62571,51.96236,{"lat":80,"lon":79},{"type":83,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR",[85],{"name":86,"class":6},"German Research Foundation","100563356","phase-3-reducing-cardiac-surgery-associated-acute-kidney-injury-occurence-by-administering-angiotensin-ii-100563356",false,"NCT06615102","Reducing Cardiac-surgery Associated Acute Kidney Injury Occurence by Administering Angiotensin II","A Prospective Angiotensin II Versus Noradrenaline Trial for Hypotension Management to Reduce Cardiac-surgery Associated Acute Kidney Injury (PAN-AKI)","PAN-AKI","Inclusion Criteria:\n\n1. Cardiac surgery using cardiopulmonary bypass including coronary artery bypass grafting (CABG) surgery, valve surgery, or combined CABG\u002Fvalve surgery\n2. Elevated risk of AKI as predicted by a score ≥ 1.5 on the following scale:\n\n   1. hemoglobin \\\u003C 130g\u002Fl = 2\n   2. creatinine \\> 1.1 mg\u002Fdl = 2\n   3. age \\> 70 years =1.5\n   4. New York Heart Association Classification (NYHA) 4 =1.5\n   5. Body Mass Index (BMI) \\> 30 =1.5\n3. Adult ≥ 18 years\n4. Written informed consent\n\nExclusion Criteria:\n\n1. Major aortic surgery (aortic arch replacement), transplant surgery, pulmonary thrombendarterectomy, ventricular assist device placement\n2. Already receiving inotropic\u002Fvasopressor support before surgery\n3. Dialysis dependent\n4. Pre-existing AKI within the last 30 days\n5. Pre-existing chronic kidney injury with an eGFR\\\u003C20 ml\u002Fmin\u002F1.73m2\n6. Pre-existing significant hypertension (persistent SBP \\> 180mmHg)\n7. Significant pulmonary hypertension (ePSAP \\> 70mmHg, mPAP \\> 40mmHg) with right ventricular systolic dysfunction (graded more severe than mild)\n8. Hypersensitivity to the active substance or to any of the excipients\n9. Pregnancy (a negative pregnancy test for women of childbearing age) or breastfeeding women\n10. Persons with any kind of dependency on the investigator or employed by the sponsor\u002Finvestigator\n11. Participation in another interventional trial within the last three months that investigates kidney function","ALL","18 Years",{"count":98,"type":99},1022,"ESTIMATED","INTERVENTIONAL",[102],"PHASE3","The study intervention focuses on exploring the use of angiotensin II as a primary vasopressor compared to norepinephrine in cardiac surgery patients to investigate whether angiotensin II can reduce the occurrence of moderate\u002Fsevere acute kidney injury (AKI). Despite its potential, as suggested by trials involving surgical patients, there is currently no human data confirming its effectiveness in preventing moderate\u002Fsevere AKI in this context. The intervention aims to address this gap by evaluating angiotensin II's impact compared to norepinephrine.",[105,106],"Cardiac Surgery","Vasoplegia",[108,109,9],"cardiac surgery","acute kidney injury","2025-07-15",{"date":112,"type":113},"2025-07-18","ACTUAL",{"date":115,"type":113},"2025-03-31",{"date":117,"type":99},"2027-04",{"name":5,"class":6},4]